Vicore Pharma has entered into an exclusive licensing agreement with Japanese pharmaceutical company Nippon Shinyaku to commercialize Vicore’s idiopathic pulmonary fibrosis (IPF) drug candidate C21 in Japan.
Sexual health pharmaceutical company Futura Medical has extended its exclusive licensing agreement with Cooper Consumer Health for the rights to commercialize its topical, gel-based erectile dysfunction treatment.
Huadong has been granted exclusive rights in Greater China to develop and commercialize MC2’s drug, Wynzora Cream, for the treatment of plaque psoriasis.
A new treatment for erectile dysfunction (ED) has received regulatory approval in the Kingdom of Saudi Arabia, a key ED market, with 10.45% of married males experiencing the condition.
WuXi Biologics expands its biologics conjugation solution center to include space for commercial manufacturing of antibody-drug conjugates for the biopharma industry.
Genentech will collaborate with biopharma company Parvus to manufacture and commercialize Navacim therapeutics for the treatment of autoimmune disease.
Lonza Pharma & Biotech will expand two of its manufacturing sites to reach the capabilities necessary to produce compounds bio-conjugates through to commercialization.